Radium-223 chloride

Drug Profile

Radium-223 chloride

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase I/II Multiple myeloma
  • Phase I Prostate cancer
  • No development reported Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 15 Nov 2017 Radium-223 chloride is still in phase I trials for Osteosarcoma (late-stage disease) in USA (IV) (NCT01833520)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Osteosarcoma(Late-stage disease) in USA (IV, Infusion)
  • 22 Sep 2017 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in USA (IV) (NCT03076203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top